Drug profile · INN
sodium polystyrene sulfonate
RESONIUM-A
sodium polystyrene sulfonate (RESONIUM-A) is a potassium sequestering agent. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral, rectal. Current US regulatory status: approved.
Drug details — sodium polystyrene sulfonate
- US status
- approved
- Class
- —
- Route
- ORAL, RECTAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sodium polystyrene sulfonate (RESONIUM-A) is a potassium sequestering agent. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral, rectal. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium sequestering agent
Primary target: Potassium
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sodium polystyrene sulfonate?
sodium polystyrene sulfonate (RESONIUM-A) is a potassium sequestering agent. Associated with Sanofi-aventis Healthcare Pty Ltd. Route of administration: oral, rectal. Current US regulatory status: approved.
What is the brand name for sodium polystyrene sulfonate?
RESONIUM-A is a marketed brand name for sodium polystyrene sulfonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sodium polystyrene sulfonate?
sodium polystyrene sulfonate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.